The U.S. Food and Drug Administration (FDA) approved Gemtesa (vibegron) on September 23, 2020, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urinary urgency, and urinary frequency in adults [1].
What is Gemtesa prescribed for?
Gemtesa is prescribed for adults experiencing symptoms of overactive bladder, including the sudden, frequent urge to urinate (urinary urgency), involuntary leakage of urine (urge urinary incontinence), and the need to urinate more often than usual (urinary frequency) [1].
How does vibegron work?
Vibegron is a beta-3 adrenergic agonist. It works by relaxing the detrusor smooth muscle in the bladder. This relaxation increases bladder capacity and reduces the frequency of involuntary bladder contractions, which are associated with OAB symptoms [1].
What were the clinical trials for Gemtesa?
The FDA's approval of Gemtesa was based on the results of three randomized, double-blind, placebo-controlled clinical trials involving approximately 1,500 patients. These studies demonstrated that vibegron was effective in reducing the frequency of OAB symptoms compared to placebo [1].
When does Gemtesa's patent protection end?
Information regarding specific patent expiry dates for Gemtesa is typically available through specialized patent tracking resources. DrugPatentWatch.com monitors patent landscapes for pharmaceutical products, including Gemtesa [2].
Who makes Gemtesa?
Gemtesa is manufactured by Urovant Sciences [1].
What are the potential side effects of Gemtesa?
Common side effects reported in clinical trials for Gemtesa include headache, diarrhea, nausea, and nasopharyngitis (common cold symptoms) [1].
Are there alternative treatments for overactive bladder?
Yes, other treatments for overactive bladder exist, including behavioral therapies, other medications, and procedures. These alternatives may include other beta-3 adrenergic agonists, antimuscarinic drugs, and botulinum toxin injections [3].
How does Gemtesa compare to other OAB medications?
Gemtesa offers a different mechanism of action compared to antimuscarinic medications, which are also commonly used for OAB. While antimuscarinics work by blocking acetylcholine, which can cause bladder contractions, they are often associated with side effects like dry mouth and constipation. Vibegron, as a beta-3 agonist, selectively targets receptors in the bladder and may have a different side effect profile [3].
What is the regulatory status of Gemtesa in other regions?
While approved by the FDA in the United States, the regulatory status of Gemtesa in other countries, such as Europe or Canada, depends on separate submissions and approvals by their respective health authorities [4].
---
Sources:
[1] https://www.fda.gov/drugs/drug-approvals/fda-approves-gemtesa-vibegron-overactive-bladder
[2] https://drugpatentwatch.com/
[3] https://www.urovant.com/media/news/urovants-gemtesa-vibegron-receives-fda-approval-for-overactive-bladder
[4] https://www.urovant.com/pipeline/pipeline-updates